title: Eculizumab experience in an adult patient with atypical hemolytic uremic syndrome.
abstract: Atypical hemolytic-uremic syndrome is a disease characterized by nonimmune hemolytic anemia, thrombocytopenia, and renal failure. In this study, we present a case of a patient with atypical hemolytic-uremic syndrome treated successfully with eculizumab. A 20-year-old female was admitted with clinical signs of atypical hemolytic syndrome. The laboratory findings were as follows: hemoglobin 9.2 g/dL, platelet count 18 × 103/μL, creatinine 4.69 mg/dL, schistocytes were in peripheral blood smear, lactate dehydrogenase 2080 U/L, and emergency plasmapheresis procedure with fresh frozen plasma were initiated. The patient was anuric within 12 h of her admittance. ADAMTS13 activity was normal. Her mother's cousin developed acute rejection immediately after receiving a renal transplant and died two months later. As she did not respond to the treatment and considering her family history, eculizumab was initiated which resulted in platelet counts starting to rise on day 5, and the patient no longer needed dialysis after 22 days.
authors.affiliation: Department of Nephrology, Antalya Training and Research Hospital, Antalya, Turkey.
authors.forename: Funda
authors.initials: F
authors.lastname: Sari
authors.affiliation: Department of Nephrology, Antalya Training and Research Hospital, Antalya, Turkey.
authors.forename: Ayça
authors.initials: A
authors.lastname: Inci
authors.affiliation: Department of Hematology, Antalya Training and Research Hospital, Antalya, Turkey.
authors.forename: Volkan
authors.initials: V
authors.lastname: Karakus
authors.affiliation: Department of Nephrology, Antalya Training and Research Hospital, Antalya, Turkey.
authors.forename: Banu
authors.initials: B
authors.lastname: Yilmaz
authors.affiliation: Department of Nephrology, Antalya Training and Research Hospital, Antalya, Turkey.
authors.forename: Metin
authors.initials: M
authors.lastname: Sarikaya
authors.affiliation: Department of Nephrology, Antalya Training and Research Hospital, Antalya, Turkey.
authors.forename: Refik
authors.initials: R
authors.lastname: Olmaz
authors.affiliation: Department of Hematology, Antalya Training and Research Hospital, Antalya, Turkey.
authors.forename: Erdal
authors.initials: E
authors.lastname: Kurtoglu
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D065766:Atypical Hemolytic Uremic Syndrome / Q000097:blood / Q000175:diagnosis / Q000188:drug therapy* / Q000276:immunology; D001792:Blood Platelets / Q000187:drug effects* / Q000276:immunology; D051056:Complement Inactivating Agents / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D010956:Plasmapheresis; D010976:Platelet Count; D006435:Renal Dialysis; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D051056:Complement Inactivating Agents; C481642:eculizumab